Hydrix Limited has announced that it has secured the exclusive rights to distribute the AngelMed Guardian^® System (Guardian) in Australia and a number of significant Asian countries including Singapore and Japan.

• The Guardian is the world's first FDA-approved, implanted cardiac monitoring device that can alert patients of an impending Acute Coronary Syndrome (ACS) event, which includes heart attacks and unstable angina.
• The faster a heart attack is diagnosed and treated, the greater the chance of a full recovery by the patient. The Guardian identifies ACS symptoms with more certainty than the patient alone and alerts them to immediately seek medical help.

The Guardian is intended for use in patients who have previously suffered an ACS event and who remain at high risk for recurrent events. The implanted device continuously monitors a patient's heart signal 24/7 and uses artificial intelligence (AI) to detect an impending heart attack

When the Guardian detects suspect heart activity, it immediately alerts the patient to seek medical attention with the implant vibrating within the chest and a separate wireless pager-like device alerting with sound and flashing LEDs.

The Guardian reduces the uncertainty of self-diagnosis. Currently, only patient recognized symptoms prompt patients to seek medical attention, but self-diagnosis of a potential heart attack is problematic